CIK 0001645113
- Large accelerated filer
NovoCure Ltd
Sign in to watch- Ticker
- NVCR
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Entity type
- Operating
- Phone
- +44 1534756700
- Business address
- NO. 4 THE FORUM, GRENVILLE STREET, ST. HELIER, Jersey
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $142,786
- in 3 filings
Net −$142,786. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-04 | Leupin Nicolas Chief Medical Officer | Grant or award | +54,975 | $18.19 | $1000K | 105,108 |
| 2025-03-04 | Leupin Nicolas Chief Medical Officer | Grant or award · Stock Options (Right to buy) | +81,499 | $18.19 | $1.5M | 81,499 |
| 2025-03-04 | Ben Arye Barak General Counsel | Grant or award | +54,975 | $18.19 | $1000K | 173,696 |
| 2025-03-04 | Ben Arye Barak General Counsel | Grant or award · Stock Options (Right to buy) | +81,499 | $18.19 | $1.5M | 81,499 |
| 2025-03-04 | Puri Michal Nath Chief Human Resources Officer | Grant or award | +54,975 | $18.19 | $1000K | 163,681 |
| 2025-03-04 | Puri Michal Nath Chief Human Resources Officer | Grant or award · Stock Options (Right to buy) | +81,499 | $18.19 | $1.5M | 81,499 |
| 2025-03-04 | Weinberg Uri Chief Innovation Officer | Grant or award | +54,975 | $18.19 | $1000K | 221,218 |
| 2025-03-04 | Weinberg Uri Chief Innovation Officer | Grant or award · Stock Options (Right to buy) | +81,499 | $18.19 | $1.5M | 81,499 |
| 2025-03-04 | Leonard Frank X EVP, Pres., Novocure Oncology | Grant or award | +54,975 | $18.19 | $1000K | 198,648 |
| 2025-03-04 | Leonard Frank X EVP, Pres., Novocure Oncology | Grant or award · Stock Options (Right to buy) | +81,499 | $18.19 | $1.5M | 81,499 |
| 2025-03-04 | Paravasthu Mukund Chief Operating Officer | Grant or award | +54,975 | $18.19 | $1000K | 84,148 |
| 2025-03-04 | Paravasthu Mukund Chief Operating Officer | Grant or award · Stock Options (Right to buy) | +81,499 | $18.19 | $1.5M | 81,499 |
| 2025-03-04 | Cordova Ashley Chief Executive Officer | Grant or award | +151,181 | $18.19 | $2.7M | 355,186 |
| 2025-03-04 | Cordova Ashley Chief Executive Officer | Grant or award · Stock Options (Right to buy) | +224,123 | $18.19 | $4.1M | 224,123 |
| 2025-03-03 | Weinberg Uri Chief Innovation Officer | Sale | −268 | $18.92 | $5K | 166,243 |
| 2025-03-03 | Leonard Frank X EVP, Pres., Novocure Oncology | Sale | −2,527 | $18.54 | $47K | 143,673 |
| 2025-03-03 | Cordova Ashley Chief Executive Officer | Sale | −2,053 | $18.54 | $38K | 204,005 |
| 2025-03-03 | Paravasthu Mukund Chief Operating Officer | Sale | −250 | $18.54 | $5K | 29,173 |
| 2025-02-28 | Weinberg Uri Chief Innovation Officer | Sale | −4,326 | $18.78 | $81K | 166,822 |
| 2025-02-28 | Weinberg Uri Chief Innovation Officer | Sale | −311 | $18.31 | $6K | 166,511 |
Page 7 of 9 · 178 trades